Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus tislelizumab versus anlotinib alone in MSS colorectal cancer after multiple prior lines
ChiCTR2200056854Phase 2Recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib and tislelizumab in colorectal cancer (CRC) and microsatellite stable colorectal cancer (2 arms), sponsored by Army Medical Center of PLA. Primary endpoint: Progression-free survival. Started May 2019; status: recruiting.
02
Drugs
anlotinibtislelizumab
03
Conditions
colorectal cancer (CRC)microsatellite stable colorectal cancer
Beyond the preview
Go deeper on ChiCTR2200056854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056854.